Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03083639 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants
A Phase 1 study of Healthy Participants, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT03083639: Completed Phase 1 study of Healthy Participants, sponsored by Takeda.
NCT03083639 is a Phase 1 study of Healthy Participants that has completed, run by Takeda. The registered enrollment target is 52 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03083639, a Phase 1 study of Healthy Participants, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the bioequivalence of esomeprazole 40 milligram (mg) tablets and capsules.
Conditions Studied
Interventions
- DRUG Esomeprazole Capsule
- DRUG Esomeprazole Tablet
Study Locations (1)
Kansas
- Pharmaceutical Research Associates, Inc. - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-03-27 |
| Est. Completion | 2017-05-13 |
| Phase | Phase 1 |
What the finished NCT03083639 record still lists
NCT03083639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Esomeprazole Capsule is the first listed.
NCT03083639 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03083639 about?
NCT03083639 is a clinical study titled "A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants". The purpose of this study is to determine the bioequivalence of esomeprazole 40 milligram (mg) tablets and capsules.
What is the current status of trial NCT03083639?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2017-03-27. Estimated completion is 2017-05-13.
What conditions does trial NCT03083639 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT03083639?
The interventions under investigation include: Esomeprazole Capsule (DRUG), Esomeprazole Tablet (DRUG).
Who is sponsoring clinical trial NCT03083639?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03083639 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03083639's enrollment target sits among peer trials
52 49th of 119 higher than 71 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI